<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03877835</url>
  </required_header>
  <id_info>
    <org_study_id>REK 2018/1934-3</org_study_id>
    <nct_id>NCT03877835</nct_id>
  </id_info>
  <brief_title>Diaphragm-sparing Nerve Blocks for Shoulder Arthroplasty</brief_title>
  <official_title>Diaphragm-sparing Nerve Blocks for Shoulder Arthroplasty: an Exploratory Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordlandssykehuset Bodo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital of North Norway</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of a modified lateral sagittal infraclavicular block and a suprascapular
      nerve block has not been studied in a cohort of total arthroplasty patients. Such
      diaphragm-sparing nerve blocks for shoulder arthroplasty may provide a very good anesthetic
      alternative in lung diseased patients who are in need for total arthroplasty of the shoulder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesized that a combination of suprascapular nerve block and lateral
      sagittal infraclavicular block of the posterior and lateral cords would provide good
      postoperative analgesia for patients undergoing shoulder arthroplasty.

      The primary aims of this study were to document numeric rating scale (NRS, 0-10) and use of
      morphine equivalents during the first 24 hours after surgery. Secondary aims were to
      determine the incidence of diaphragm paresis 30 minutes after the block and to quantify
      postoperative hand grip force at 1 hr.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single intervention</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Outcome measures will be performed by an independent assessor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>NRS</measure>
    <time_frame>Postoperatively at 1 hour</time_frame>
    <description>Pain on a 0-10 scale where 0=no pain and 10=unbearable pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence ipsilateral hemidiaphragmatic paralysis after 30 minutes</measure>
    <time_frame>30 minutes after the blocks</time_frame>
    <description>Hemidiaphragmatic paralysis was defined as the absence of diaphragmatic motion during normal respiration, coupled with absent or (paradoxical) cranial diaphragmatic movement when the patient forcefully sniffed.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Shoulder Disease</condition>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>SSNB will be performed with 4 ml ropivacaine 5 mg/ml LSIB will be performed With 15 ml ropivacaine 7.5 mg/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral nerve blocks</intervention_name>
    <description>LSIB + SSNB</description>
    <arm_group_label>Ropivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years old,

          -  BMI 20-35 kg.m-2

          -  ASA physical status 1-3

        Exclusion Criteria:

          -  unable to concent,

          -  pregnancy,

          -  pre-existing severe respiratory disease,

          -  use of anticoagulation drugs other than acetylsalicylic acid or dipyridamol,

          -  allergy to local anaesthetics,

          -  patients on regular opioids,

          -  atrioventricular block,

          -  peripheral neuropathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <state>Troms</state>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva-Hanne Hansen</last_name>
      <phone>+4795259201</phone>
      <email>eva-hanne.hansen@unn.no</email>
    </contact>
    <investigator>
      <last_name>Dario F Musso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars M Ytrebø, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oivind Klaastad, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

